<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686085</url>
  </required_header>
  <id_info>
    <org_study_id>vaginal dinoprostone nullipara</org_study_id>
    <nct_id>NCT03686085</nct_id>
  </id_info>
  <brief_title>Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.</brief_title>
  <official_title>Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether vaginal dinoprostone administered before intrauterine device (IUD)
      insertion reduces failed insertions, insertion-related complications and pain in nulliparous
      women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women may experience pain and technical difﬁculties may be encountered when insertion of an
      intrauterine device (IUD) is attempted through a narrow cervical canal.IUD insertion- related
      complications and side effects are more common among women who had never delivered
      vaginally.n American College of Obstetricians and Gynecologists committee opinion encourages
      providers to use IUDs as a ﬁrst line of contraception in nulliparous women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">March 10, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provider ease of insertion</measure>
    <time_frame>5 minutes</time_frame>
    <description>Provider ease of insertion was evaluated using a visual analog scale from 0 to 10 cm where 0 denotes very easy insertion and 10 denotes a very difficult insertion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference in the pain intensity scores between the study groups</measure>
    <time_frame>5 minutes</time_frame>
    <description>the difference in the pain intensity scores between the study groups at IUD insertion BY10 cm visual analog scale score where 0 denotes no pain and 10 denotes the most imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insertion time</measure>
    <time_frame>10 minutes</time_frame>
    <description>IUD insertion time from speculum in to speculum out</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Intrauterine Device</condition>
  <arm_group>
    <arm_group_label>dinoprostone arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 3 mg</intervention_name>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.</description>
    <arm_group_label>dinoprostone arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo vaginal tablet</intervention_name>
    <description>1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous women aged over 18 years of age requesting a copper IUD for contraception,
             had a negative pregnancy test.

        Exclusion Criteria:

          -  • a prior pregnancy greater than 20 weeks of duration

               -  currently pregnant or were pregnant within 6 weeks of study entry

               -  had a prior attempted or successful IUD insertion

               -  had a history of a cervical procedure such as cone biopsy, Loop electrosurgical
                  excision procedure, or cryotherapy

               -  any World Health Organization Medical Eligibility Criteria category 3 or 4
                  precaution to an IUD

               -  active vaginitis or cervicitis

               -  undiagnosed abnormal uterine bleeding

               -  pelvic inﬂammatory disease within the last 3 months

               -  ﬁbroids or other uterine abnormalities distorting the uterine cavity

               -  contraindication to dinoprostone.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Cairo University</name>
      <address>
        <city>Giza</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>June 28, 2020</last_update_submitted>
  <last_update_submitted_qc>June 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>lecturer in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

